Nepafenac

CAS No. 78281-72-8

Nepafenac( AHR-9434 | AL-6515 )

Catalog No. M15955 CAS No. 78281-72-8

A nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 activity; a prodrug of amfenac.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 41 In Stock
100MG 109 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Nepafenac
  • Note
    Research use only, not for human use.
  • Brief Description
    A nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 activity; a prodrug of amfenac.
  • Description
    A nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 activity; a prodrug of amfenac.Other Indication Approved.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    AHR-9434 | AL-6515
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX-1|COX-2
  • Research Area
    Other Indications
  • Indication
    Other Disease

Chemical Information

  • CAS Number
    78281-72-8
  • Formula Weight
    254.2839
  • Molecular Formula
    C15H14N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 32 mg/mL
  • SMILES
    O=C(N)CC1=CC=CC(C(C2=CC=CC=C2)=O)=C1N
  • Chemical Name
    Benzeneacetamide, 2-amino-3-benzoyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Gamache DA, et al. Inflammation. 2000 Aug;24(4):357-70. 2. Singh RP, et al. Ophthalmology. 2017 Jun;124(6):776-785. 3. Abu Hussein NB, et al .J Ophthalmol. 2017;2017:3765253.
molnova catalog
related products
  • Sifalimumab

    Sifalimumab (MEDI-545) is a monoclonal antibody that targets IFNα and suppresses abnormal immune activity by binding to interferon-alpha.Sifalimumab is used for the treatment of moderate to severe SLE.

  • Continentalic acid

    Continentalic acid from Aralia continentalis has minimum inhibitory concentrations (MICs) of approximately 8-16 μg/mL against S. aureus.

  • Rebamipide mofetil

    Rebamipide mofetil is an orally active prodrug of Rebamipide which is a mucoprotective agent.